Table 2.
Baseline characteristics.
| Characteristics | POLARx (n = 65) | AFA (n = 531) | p-Value |
|---|---|---|---|
| Age (years) | 65.0 ± 11.6 | 63.0 ± 27.9 | 0.221 |
| Gender, female | 20 (31%) | 132 (25%) | 0.067 |
| BMI (kg/m2) | 30.6 ± 8.8 | 28.6 ± 5.7 | 0.060 |
| LVEF (%) | 52.8 ± 7.7 | 53.6 ± 4.1 | 0.137 |
| Cardiomyopathy | 8 (12%) | 43 (8%) | 0.087 |
| Hypertension | 37 (57%) | 220 (41%) | <0.001 * |
| Diabetes mellitus | 7 (11%) | 80 (15%) | 0.104 |
| Beta blocker | 54 (83%) | 421 (79%) | 0.101 |
| AADs | 5 (8%) | 40 (8%) | 0.173 |
| PAF | 43 (66%) | 281 (53%) | 0.018 * |
| Early recurrence | 7 (11%) | 51 (10%) | 0.148 |
Continuous variables are shown as the mean ± SD and categorical variables as the number (%). A p-value ≤ 0.05 indicates statistical significance. BMI, body mass index, LVEF, left ventricular ejection fraction, LA, left atrium, AADs, antiarrhythmic agents, PAF, paroxysmal arterial fibrillation. * and bold letters indicate statistical significance.